Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3)

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.

Study Overview

• Status: Enrolling by invitation
• Conditions: Kidney Diseases; Urologic Diseases; Genetic Disease; Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 2 (PH2); Primary Hyperoxaluria Type 3 (PH3)
• Intervention / Treatment: Drug: DCR-PHXC

• Study Type: Interventional
• Enrollment (Estimated): 75
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Melbourne, Australia, 3052
    • Clinical Trial Site
  • Queensland
    • Herston, Queensland, Australia, 4029
      • Clinical Research Site
• Canada
  • Ontario
    • Hamilton, Ontario, Canada, L8S 4K1
      • Clinical Research Site
• France
  • Bron, France, 69500
    • Clinical Trial Site
  • Paris, France, 75019
    • Clinical Trial Site
• Germany
  • Bonn, Germany, 53127
    • Clinical Trial Site
  • Heidelberg, Germany, 69120
    • Clinical Trial Site
• Italy
  • Roma, Italy, 00165
    • Clinical Research Site
• Japan
  • Fukuoka, Japan, 830-0011
    • Clinical Trial Site
  • Nagoya, Japan, 467-8601
    • Clinical Trial Site
  • Tokyo, Japan, 183-8561
    • Clinical Trial Site
• Lebanon
  • Beirut, Lebanon
    • Clinical Trial Site
• Netherlands
  • Amsterdam, Netherlands, 1105AZ
    • Clinical Trial Site
• Norway
  • Tromsø, Norway, 9019
    • Clinical Trial Site
• Spain
  • Barcelona, Spain, 08035
    • Clinical Trial Site
  • Barcelona, Spain, 08035
    • Clinical Research Site
• Turkey
  • Ankara, Turkey, 06560
    • Clinical Trial Site
• United Kingdom
  • Birmingham, United Kingdom
    • Clinical Trial Site
  • London
    • Hampstead, London, United Kingdom
      • Clinical Trial Site
• United States
  • California
    • San Francisco, California, United States, 94143
      • Clinical Research Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Clinical Trial Site
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Clinical Trial Site
  • New York
    • New York, New York, United States, 10016
      • Clinical Trial Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

•Participant successfully completed a Dicerna Pharmaceuticals, Inc. study of DCR PHXC.

OR Participant is the sibling of a participant who successfully completed a Dicerna Pharmaceuticals, Inc. study of DCR PHXC. Siblings must be younger than 18 years of age and must have genetically confirmed PH.

• For participants rolling over from a multidose study of DCR-PHXC, enrollment should occur within a window of 25 to 75 days from the last dose of study intervention.
• Estimated GFR at screening ≥ 30 mL/min normalized to 1.73 m2 body surface area (BSA), calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formula in participants aged ≥ 18 years, or the multivariate equation by Schwartz in participants aged 12 months to 17 years. In Japan, the cystatin C-based Uemura formula will be used for participants aged 12 months to <2 years, the creatinine-based Uemura formula by will be used for participants aged 2 to 17 years, and the equation by Matsuo will be used in participants aged ≥ 18 years.

Key Exclusion Criteria:

• Renal or hepatic transplantation (prior or planned within the study period)
• Plasma oxalate > 30 µmol/L
• Currently on dialysis
• Documented evidence of clinical manifestations of systemic oxalosis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Open Label; Open label, monthly subcutaneous injection	Drug: DCR-PHXC; Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection; Other Names: Nedosiran

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The annual rate of decline in eGFR in participants with PH1	To evaluate the effect of DCR PHXC on estimated glomerular filtration rate (eGFR) in participants with PH1	Annual change from baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the efficacy of DCR PHXC in reducing Uox burden in patients with PH: TWS AUC	Time-weighted standardized area under the curve (TWS AUC) of 24-hour Uox from Day 90 to Day 180, based on percent change from Baseline in PH1, PH2, and PH3 participant subgroups. This endpoint will only be assessed in participants previously randomized to placebo in a previous study of DCR- PHXC and pediatric siblings.	Monthly for 4 months (D90 through D180)
The incidence and severity of treatment-emergent adverse events (TEAE) and SAEs associated with abnormal 12 lead electrocardiogram (ECG) readings	To evaluate the safety and tolerability of DCR PHXC when administered monthly to patients with primary hyperoxaluria (PH) via change from baseline and abnormal ECG findings. Standard 12-lead ECGs will be performed in the supine position after the subject has rested comfortably for 10 minutes. The parameters assessed will be rhythm, ventricular rate, PR interval, QRS duration, QT interval, and corrected QT interval (QTcF, Fridericia correction). The Investigator or designee is responsible for reviewing the ECG(s) to assess whether the results are within normal limits and to determine the clinical significance of the results. Standardized ECG acquisition equipment will be provided to all clinical trial sites at the start of the trial, to ensure parity across all sites.	TEAEs and SAEs are evaluated monthly for 6 years
The incidence and severity of treatment-emergent adverse events (TEAE) and SAEs associated with abnormal physical examination findings	To evaluate the safety and tolerability of DCR PHXC when administered monthly to patients with primary hyperoxaluria (PH) via change from baseline and incidence of abnormal physical exam findings. A full physical examination will include a complete review of body systems: eyes, ears, nose, and throat, chest/respiratory, heart/cardiovascular, gastrointestinal/liver, musculoskeletal/extremities, dermatological/skin, thyroid/neck, lymph nodes, and neurological. A full physical exam is done at Screening, Day 180 and if a participant ends the study early. A brief physical examination will minimally include chest/respiratory, heart/cardiovascular, dermatological/skin, and gastrointestinal/liver. A brief physical examination will be performed at the Investigator's discretion at all other visits.	TEAEs and SAEs are evaluated monthly for 6 years
The incidence and severity of treatment-emergent adverse events (TEAE) and SAEs associated with abnormal vital signs	To evaluate the safety and tolerability of DCR PHXC when administered monthly to patients with primary hyperoxaluria (PH) via the change from baseline and incidence of abnormal vital signs. Vital signs include blood pressure, pulse/heart rate, oral body temperature, and respiratory rate. Parameters will be measured in the supine position, using an automated instrument or manually, after the participant has rested comfortably for 10 minutes. In the pediatric population, an age-appropriate cuff size should be used for blood pressure measurements. Temperature will be obtained in degrees Celsius (°C), pulse rate will be counted for a full minute and recorded in beats per minute, and respirations will be counted for a full minute and recorded in breaths per minute.	TEAEs and SAEs are evaluated monthly for 6 years
The incidence and severity of treatment-emergent adverse events (TEAE) and SAEs related to abnormal clinical laboratory tests (hematology, chemistry, coagulation parameters, and urinalysis)	To evaluate the safety and tolerability of DCR PHXC when administered monthly to patients with primary hyperoxaluria (PH) via the change from baseline and incidence of abnormal clinical laboratory tests.	TEAEs and SAEs are evaluated monthly for 6 years
To identify the proportion of participants with normalized or near-normalized 24 hour urinary oxalate (Uox)	The proportion of participants with a 24 hour Uox level (< 0.46 mmol/24 hours or ≥ 0.46 - < 0.60 mmol/24 hours [adjusted per 1.73 m2 body surface area (BSA) in participants aged < 18 years]) at each assessment time point throughout the study in PH1, PH2, and PH3 participant subgroups	24 hour urine collections (if applicable) are performed monthly for 6 months (or quarterly for PH1 multidose rollovers), quarterly for 2 1/2 years (or monthly for PH2/PH3 multidose rollovers until Month 12), and every 6 months for 3 years after that.
To identify the percentage of participants with spot urinary oxalate-to-creatinine ratio ≤ the ULN or ≤ 1.5 x ULN	The percentage of participants with spot urinary oxalate-to-creatinine ratio ≤ the ULN or ≤ 1.5 x ULN at each assessment time point throughout the study in PH1, PH2, and PH3 participant subgroups	Spot urine collections are performed monthly for 6 months (or quarterly for PH1 multidose rollovers), quarterly for 2 1/2 years (or monthly for PH2/PH3 multidose rollovers until Month 12), and every 6 months for 3 years after that.
To assess the effect of DCR-PHXC on stone events in patients with PH	Change from Baseline in the number of stone events over a 12-month period, annually in Year 1, Year 2, etc. in PH1, PH2, and PH3 participant subgroups	Evaluated yearly for 6 years
To assess the effect of DCR-PHXC on stone burden grade in patients with PH	Change from Baseline in the stone burden grade at Year 1, Year 2, etc. in PH1, PH2, and PH3 participant subgroups	Evaluated yearly for 6 years
To assess the effect of DCR-PHXC in nephrocalcinosis grade in patients with PH	Change from Baseline in nephrocalcinosis grade at Year 1, Year 2, etc. in PH1, PH2, and PH3 participant subgroups	Evaluated yearly for 6 years
To evaluate the incidence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in participants with PH	The number of participants with severe CKD (GFR = 15-29 mL/min) or ESRD (GFR <15 mL/min); adjusted per 1.73 m2 BSA in participants aged < 18 years in PH1, PH2, and PH3 participant subgroups	eGFR is evaluated monthly for 6 months (or quarterly for multidose rollovers), quarterly for 2 1/2 years, and every 6 months for 3 years after that.
Change from Baseline in the Short Form (36) Health Survey (SF-36®) in PH1, PH2, and PH3 participant subgroups	To evaluate the effect of DCR-PHXC on Quality of Life (QoL) assessments in patients with PH. The SF 36 is a set of generic, coherent, and easily administered quality-of-life measures that taps 8 health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. The 36 items are identical to the MOS SF 36 described in Ware and Sherbourne (1992). Participants respond to each item on a categorical scale. Categorical answers are transformed to a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state.	Surveys are administered at screening, Day 180, yearly for 3.5 years, then at Month 72 (EOS).
Change from Baseline in the EQ-5D-5L™ in adults in PH1, PH2, and PH3 participant subgroups	To evaluate the effect of DCR-PHXC on Quality of Life (QoL) assessments in patients with PH. The EQ-5D-5L consists of the EQ 5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system has 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The digits for the 5 dimensions can be combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's self-rated health on a 20-cm vertical VAS, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine.' Participants are asked to place an "X" on the line that represents their health on that day.	Surveys are administered at screening, Day 180, yearly for 3.5 years, then at Month 72 (EOS).
Change from Baseline in the Pediatric Quality of Life Inventory (PedsQL™) in children in PH1, PH2, and PH3 participant subgroups	To evaluate the effect of DCR-PHXC on Quality of Life (QoL) assessments in patients with PH. The 23-item PedsQL is comprised of 5 items in the Emotional, Social, and School Functioning dimensions (Psychosocial Health) and 8 items in the Physical Functioning (Physical Health) dimension. Items are reverse-scored on a 0 to 4 Likert scale and linearly transformed to a 0 to 100 scale, so that higher scores indicate better functioning and HRQOL. Scale Scores are the sum of the items in each dimension, divided by the number of items answered.	Surveys are administered at screening, Day 180, yearly for 3.5 years, then at Month 72 (EOS).
To assess the long-term efficacy of DCR PHXC in reducing Uox burden in patients with PH	Percent change from Baseline in 24-hour Uox at each assessment time point throughout the study in PH1, PH2, and PH3 participant subgroups. In those participants randomized to placebo in a previous study of DCR-PHXC and pediatric siblings, this endpoint will be assessed only after Month 6	24 hour urine collections (if applicable) are performed monthly for 6 months (or quarterly for PH1 multidose rollovers), quarterly for 2 1/2 years (or monthly for PH2/PH3 multidose rollovers until Month 12), and every 6 months for 3 years after that.
To assess the long-term efficacy of DCR-PHXC in reducing Uox burden in patients with PH	Percent and absolute change from Baseline in spot urinary oxalate-to-creatinine ratio at each assessment time point throughout the study in PH1, PH2, and PH3 participant subgroups. In pediatric siblings, this endpoint will be assessed only after Month 6	Spot urine collections are performed monthly for 6 months (or quarterly for PH1 multidose rollovers), quarterly for 2 1/2 years (or monthly for PH2/PH3 multidose rollovers until Month 12), and every 6 months for 3 years after that.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the effect of DCR PHXC on eGFR in participants with PH2 and PH3	The annual rate of decline in eGFR in participants with PH2 and PH3	Annual change from baseline
To characterize the PK of DCR PHXC in patients with PH by observing minimum concentration (Cmin).	Population and/or individual pharmacokinetic (PK) parameters for DCR PHXC, including minimum observed concentration (Cmin)	Participants rolling from a single dose study will be analyzed at Day 1, Day 2, Day 30, Day 31, Day 150, and Day 180; multidose rollovers will just collect Day 1 and 180. Then there will be analyses every 6 months for 2.5 years, and annually for 3 years.
To characterize the PK of DCR PHXC in patients with PH by observing maximum concentration (Tmax).	Population and/or individual pharmacokinetic (PK) parameters for DCR PHXC, including time to maximum concentration (Tmax)	Participants rolling from a single dose study will be analyzed at Day 1, Day 2, Day 30, Day 31, Day 150, and Day 180; multidose rollovers will just collect Day 1 and 180. Then there will be analyses every 6 months for 2.5 years, and annually for 3 years.
To characterize the PK of DCR PHXC in patients with PH by observing terminal elimination half-life (t1/2).	Population and/or individual pharmacokinetic (PK) parameters for DCR PHXC, including terminal elimination half-life (t1/2)	Participants rolling from a single dose study will be analyzed at Day 1, Day 2, Day 30, Day 31, Day 150, and Day 180; multidose rollovers will just collect Day 1 and 180. Then there will be analyses every 6 months for 2.5 years, and annually for 3 years.
To characterize the PK of DCR PHXC in patients with PH by observing clearance.	Population and/or individual pharmacokinetic (PK) parameters for DCR PHXC, including clearance (CL)	Participants rolling from a single dose study will be analyzed at Day 1, Day 2, Day 30, Day 31, Day 150, and Day 180; multidose rollovers will just collect Day 1 and 180. Then there will be analyses every 6 months for 2.5 years, and annually for 3 years.
To characterize the PK of DCR PHXC in patients with PH by observing volume of distribution of estimates.	Population and/or individual pharmacokinetic (PK) parameters for DCR PHXC, including volume of distribution (V) estimates	Participants rolling from a single dose study will be analyzed at Day 1, Day 2, Day 30, Day 31, Day 150, and Day 180; multidose rollovers will just collect Day 1 and 180. Then there will be analyses every 6 months for 2.5 years, and annually for 3 years.
To characterize the PK of DCR PHXC in patients with PH by observing the area under the curve (AUC)	Population and/or individual pharmacokinetic (PK) parameters for DCR PHXC, including secondary parameters of area under the curve (AUC)	Participants rolling from a single dose study will be analyzed at Day 1, Day 2, Day 30, Day 31, Day 150, and Day 180; multidose rollovers will just collect Day 1 and 180. Then there will be analyses every 6 months for 2.5 years, and annually for 3 years.
To characterize the PK of DCR PHXC in patients with PH by observing maximum observed concentration (Cmax).	Population and/or individual pharmacokinetic (PK) parameters for DCR PHXC, including maximum observed concentration (Cmax)	Participants rolling from a single dose study will be analyzed at Day 1, Day 2, Day 30, Day 31, Day 150, and Day 180; multidose rollovers will just collect Day 1 and 180. Then there will be analyses every 6 months for 2.5 years, and annually for 3 years.

Collaborators and Investigators

• Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
• Investigators: Study Director: Verity Rawson, MB.CHB, Dicerna, A Novo Nordisk Company

Study record dates

Study Major Dates

• Study Start (Actual): July 9, 2019
• Primary Completion (Estimated): April 1, 2030
• Study Completion (Estimated): April 1, 2030

Study Registration Dates

• First Submitted: July 10, 2019
• First Submitted That Met QC Criteria: July 30, 2019
• First Posted (Actual): August 2, 2019

Study Record Updates

• Last Update Posted (Actual): January 12, 2024
• Last Update Submitted That Met QC Criteria: January 10, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: siRNA; RNAi; PH1; PH2; Primary Hyperoxaluria; GalNAc; LDH; PH3; LDHA
• Additional Relevant MeSH Terms: Metabolic Diseases; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Hyperoxaluria; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Genetic Diseases, Inborn; Urologic Diseases; Hyperoxaluria, Primary
• Other Study ID Numbers: DCR-PHXC-301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes